Generic Name and Formulations:
Ciclesonide 50mcg/spray; aqueous nasal spray.
Indications for OMNARIS:
Treatment of seasonal allergic rhinitis in patients ≥6yrs old and perennial allergic rhinitis in patients ≥12yrs old.
2 sprays in each nostril once daily (200mcg/day).
Seasonal allergic rhinitis: <6yrs: not recommended. ≥6yrs: 2 sprays in each nostril once daily (200mcg/day).
Avoid use in patients with recent nasal ulcers/surgery/trauma until healed. Potential worsening of active tuberculosis; fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. If exposed to measles or chickenpox, consider immunoglobulin prophylactic therapy. If adrenal suppression exists following systemic corticosteroid therapy, replacement with topical steroids may exacerbate symptoms of adrenal insufficiency. Monitor for hypercorticism and HPA axis suppression (if occur discontinue slowly), and for candida infection and other nasal mucosal changes. Monitor for vision changes or with history of increased intraocular pressure, glaucoma and/or cataracts. Monitor for growth suppression in children. Avoid spraying eyes, or directly onto the nasal septum. Reevaluate if no improvement after 2 weeks (for seasonal allergic rhinitis) and 5 weeks (for perennial allergic rhinitis). Pregnancy (Cat. C). Nursing mothers.
May be potentiated by ketoconazole.
Headache, epistaxis, nasopharyngitis, ear pain, pharyngolaryngeal pain.
Nasal spray (pump)—12.5g (120 sprays)
Neurology Advisor Articles
- Optimizing Treatment for Patients With Chronic Sciatica: Gabapentin vs Pregabalin
- Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis
- Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions
- A New Look at Demyelination and White Matter Density in Multiple Sclerosis
- Early Onset of Efficacy After Erenumab Treatment in Chronic and Episodic Migraines